drugset / Trial / NCT04281420
A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, open-label clinical study with separate Dose Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of ATG-019, a dual inhibitor of PAK4 and NAMPT, alone or co-administered with starting dose of 500 mg niacin ER in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).
Timeline
- Start
- 2020-04-13
- Primary completion
- 2023-10-02
- Completion
- 2023-10-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niacin | Small molecule | 500 mg | Oral |
| Subject | PADNARSERTIB | Small molecule | 30 mg | Oral |
| Subject | PADNARSERTIB | Small molecule | 60 mg | Oral |